Assessment of the efficacy of spironolactone for COVID-19 ARDS patients

Aysin ERSOY; Bülent Barış GÜVEN; Tuna ERTÜRK; Fulya YURTSEVER; Zöhre KARAMAN; Temel GÜNER; Özge KÖMPE

Makale detayları

Assessment of the efficacy of spironolactone for COVID-19 ARDS patients

Yazarlar:

Aysin ERSOY | Bülent Barış GÜVEN | Tuna ERTÜRK | Fulya YURTSEVER | Zöhre KARAMAN | Temel GÜNER | Özge KÖMPE

Yayıncı:

Istanbul Aydin University

Ana Başlıklar:

Hastalıklar

Dergi:

Aydın Journal of Health 2021 Vol.7 Issue 3, pp.191-209

Belge Tipi:

Makale

Yayın Tarihi:

10/2021

Belge Dili:

İngilizce

Document ID (Org No.):

2000921108

Sıklık:

Aylık

eISSN:

2717-6800

pISSN:

2149-5769

Özet:

 

INTRODUCTION AND AIM
The aim of our study is to compare patients monitored for ARDS diagnosis linked to COVID-19 treated with spironolactone with patients who did not use spironolactone and to retrospectively identify whether there was any positive effect on mortality using clinical and laboratory data from patients.
MATERIAL AND METHOD
Two groups were created of patients treated due to severe ARDS diagnosis linked to COVID-19 from one group administered spironolactone (Group S, n=30) and the other group not administered spironolactone (Group F, n=30). Groups were compared in terms of demographic characteristics, presence of comorbidity, inotropic agent requirements, days of admission, days of mechanical ventilation and mortality. Additionally, fever, PO2/FIO2 (Horowitz ratio), lymphocyte count, CRP value, SOFA scorer, and d-dimer levels on the day of admission, 1st day, 3rd day, 5th day, 8th day, 12th day, day of discharge or day of exitus were compared between the groups and statistically analyzed.
RESULTS
Group S were found to have higher days of admission and days of mechanical ventilation compared to Group F. Group F had significantly higher mortality rate compared to Group S. The final Horowitz value in Group F was found to be significantly lower compared to Group S. The lymphocyte values in Group F were significantly lower than Group S on the 1st, 3rd, 5th, 8th and 12th day and at the final measurement. The CRP values in Group F were significantly higher than Group S on the 3rd, 5th, 8th and 12th day and at the final measurement. The SOFA scores on the 8th and 12th days and at the final measurement in Group F were found to be significantly higher than GroupS.
CONCLUSION
In our study, parameters for disease severity regressed, patients survived for longer and mortality was identified to be lower in the group using spironolactone.

Makale detayları

Assessment of the efficacy of spironolactone for COVID-19 ARDS patients

Yazarlar: Aysin ERSOY | Bülent Barış GÜVEN | Tuna ERTÜRK | Fulya YURTSEVER | Zöhre KARAMAN | Temel GÜNER | Özge KÖMPE

Yayıncı: Istanbul Aydin University

Ana Başlıklar: Hastalıklar

Dergi: Aydın Journal of Health 2021 Vol.7 Issue 3, pp.191-209

Belge Tipi: Makale

Yayın Tarihi: 10/2021

Belge Dili: İngilizce

Document ID (Org No.): 2000921108

Sıklık: Aylık

eISSN: 2717-6800

pISSN: 2149-5769

Sayı

Yazarlar:

Aysin ERSOY | Bülent Barış GÜVEN | Tuna ERTÜRK | Fulya YURTSEVER | Zöhre KARAMAN | Temel GÜNER | Özge KÖMPE

Yayıncı:

Istanbul Aydin University

Ana Başlıklar:

Hastalıklar

Dergi:

Aydın Journal of Health 2021 Vol.7 Issue 3, pp.191-209

Belge Tipi:

Makale

Yayın Tarihi:

10/2021

Belge Dili:

İngilizce

Document ID (Org No.):

2000921108

Sıklık:

Aylık

eISSN:

2717-6800

pISSN:

2149-5769